Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01973062 · OUTCOME

Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma · Source last updated 2020-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 30 days following the last dose of study treatment

What was measured

Number of patients with toxicities related to the study drug

Analysis population: Only one patient registered. No patient data analyzed

Groups in this outcome

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan

Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Number of patients with toxicities related to the study drug
groups
  1. description
    Patients receive rituximab IV on day 1. Within 7 to 9 days, patients receive rituximab IV and yttrium Y 90 ibritumomab tiuxetan IV in the absence of disease progression or unacceptable toxicity. rituximab: Given IV yttrium Y 90 ibritumomab tiuxetan: Given IV
    id
    OG000
    title
    Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan
population Description
Only one patient registered. No patient data analyzed
reporting Status
POSTED
time Frame
Up to 30 days following the last dose of study treatment
title
Establish the Toxicity Profile of Ibritumomab Tiuxetan in This Patient Population.
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice